Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism

S. H. Lin, Y. F. Lin, K. C. Lu, L. K. Diang, S. H. Chyr, W. K. Liao, S. D. Shieh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Secondary hyperparathyroidism in chronic renal failure may contribute to abnormalities of lipid metabolism and glucose tolerance. Amelioration of secondary hyperparathyroidism has been reported to mitigate the hyperlipidaemia and improve glucose tolerance experimentally. The effect of the partial suppression of hyperparathyroidism by intravenous calcitriol on lipid levels and glucose tolerance was studied in 15 haemodialysis patients with secondary hyperparathyroidism. All received intravenous calcitriol 1 μg at the end of haemodialysis thrice weekly for eight weeks. Oral glucose tolerance test and plasma lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apoprotein A-I and apoprotein B were determined simultaneously before and after eight weeks of therapy. Before calcitriol treatment, uraemic patients with secondary hyperparathyroidism displayed a significant higher triglyceride and a significant lower HDL-C and apoprotein A-I as well as marked glucose intolerance with an increment of the area below the glucose curve when compared with healthy control subjects. After eight weeks of calcitriol treatment, there was a significant decrement in serum intact parathyroid hormone (476.45 ± 48.33 versus 191.37 ± 30.17 ng/l, P <0.001) and plasma triglyceride (2.24 ± 0.34 versus 1.80 ± 0.29 mmol/l, P <0.05) as well as a significant increment of plasma apoprotein A-I (38.13 ± 2.14 versus 44.19 ± 2.18 μmol/l, P <0.05), whereas there was no significant change in serum total cholesterol, LDL-C, HDL-C, and apoprotein B. These patients also became more glucose tolerant with a significant decrease of the area below the glucose curve and a significant rise in the area under the insulin curve after glucose load. Furthermore, the insulinogenic index increased significantly. It was concluded that in addition to 1,25-dihydroxyvitamin D3 deficiency, secondary hyperparathyroidism may participate in the abnormal lipid metabolism, glucose tolerance and insulin secretion seen in dialysis patients and these abnormalities could be, at least in part, improved by intravenous calcitriol treatment.

Original languageEnglish
Pages (from-to)533-538
Number of pages6
JournalClinical Science
Volume87
Issue number5
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Secondary Hyperparathyroidism
Calcitriol
Lipids
Glucose
Apoproteins
HDL Cholesterol
Triglycerides
Apolipoproteins B
Lipid Metabolism
LDL Cholesterol
Renal Dialysis
Cholesterol
Insulin
Glucose Intolerance
Hyperparathyroidism
Therapeutics
Glucose Tolerance Test
Hyperlipidemias
Parathyroid Hormone
Serum

Keywords

  • 1,25-(OH)D, 1,25-dihydroxyvitamin D
  • alb, albumin
  • apo, apoprotein
  • HDL-C, high density lipoprotein cholesterol
  • HTGL, hepatic triglyceride lipase
  • I-PTH, intact parathyroid hormone
  • ICa, ionized calcium
  • InP, inorganic phosphorus
  • LDL-C, low density lipoprotein cholesterol
  • LPL, lipoprotein lipase
  • OGTT, oral glucose tolerance test
  • PTH, parathyroid hormone
  • TC, total cholesterol
  • TCa, total calcium
  • TG, triglyceride

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, S. H., Lin, Y. F., Lu, K. C., Diang, L. K., Chyr, S. H., Liao, W. K., & Shieh, S. D. (1994). Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clinical Science, 87(5), 533-538.

Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. / Lin, S. H.; Lin, Y. F.; Lu, K. C.; Diang, L. K.; Chyr, S. H.; Liao, W. K.; Shieh, S. D.

In: Clinical Science, Vol. 87, No. 5, 1994, p. 533-538.

Research output: Contribution to journalArticle

Lin, S. H. ; Lin, Y. F. ; Lu, K. C. ; Diang, L. K. ; Chyr, S. H. ; Liao, W. K. ; Shieh, S. D. / Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. In: Clinical Science. 1994 ; Vol. 87, No. 5. pp. 533-538.
@article{ca579a1e3bca499983b71465c5905804,
title = "Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism",
abstract = "Secondary hyperparathyroidism in chronic renal failure may contribute to abnormalities of lipid metabolism and glucose tolerance. Amelioration of secondary hyperparathyroidism has been reported to mitigate the hyperlipidaemia and improve glucose tolerance experimentally. The effect of the partial suppression of hyperparathyroidism by intravenous calcitriol on lipid levels and glucose tolerance was studied in 15 haemodialysis patients with secondary hyperparathyroidism. All received intravenous calcitriol 1 μg at the end of haemodialysis thrice weekly for eight weeks. Oral glucose tolerance test and plasma lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apoprotein A-I and apoprotein B were determined simultaneously before and after eight weeks of therapy. Before calcitriol treatment, uraemic patients with secondary hyperparathyroidism displayed a significant higher triglyceride and a significant lower HDL-C and apoprotein A-I as well as marked glucose intolerance with an increment of the area below the glucose curve when compared with healthy control subjects. After eight weeks of calcitriol treatment, there was a significant decrement in serum intact parathyroid hormone (476.45 ± 48.33 versus 191.37 ± 30.17 ng/l, P <0.001) and plasma triglyceride (2.24 ± 0.34 versus 1.80 ± 0.29 mmol/l, P <0.05) as well as a significant increment of plasma apoprotein A-I (38.13 ± 2.14 versus 44.19 ± 2.18 μmol/l, P <0.05), whereas there was no significant change in serum total cholesterol, LDL-C, HDL-C, and apoprotein B. These patients also became more glucose tolerant with a significant decrease of the area below the glucose curve and a significant rise in the area under the insulin curve after glucose load. Furthermore, the insulinogenic index increased significantly. It was concluded that in addition to 1,25-dihydroxyvitamin D3 deficiency, secondary hyperparathyroidism may participate in the abnormal lipid metabolism, glucose tolerance and insulin secretion seen in dialysis patients and these abnormalities could be, at least in part, improved by intravenous calcitriol treatment.",
keywords = "1,25-(OH)D, 1,25-dihydroxyvitamin D, alb, albumin, apo, apoprotein, HDL-C, high density lipoprotein cholesterol, HTGL, hepatic triglyceride lipase, I-PTH, intact parathyroid hormone, ICa, ionized calcium, InP, inorganic phosphorus, LDL-C, low density lipoprotein cholesterol, LPL, lipoprotein lipase, OGTT, oral glucose tolerance test, PTH, parathyroid hormone, TC, total cholesterol, TCa, total calcium, TG, triglyceride",
author = "Lin, {S. H.} and Lin, {Y. F.} and Lu, {K. C.} and Diang, {L. K.} and Chyr, {S. H.} and Liao, {W. K.} and Shieh, {S. D.}",
year = "1994",
language = "English",
volume = "87",
pages = "533--538",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism

AU - Lin, S. H.

AU - Lin, Y. F.

AU - Lu, K. C.

AU - Diang, L. K.

AU - Chyr, S. H.

AU - Liao, W. K.

AU - Shieh, S. D.

PY - 1994

Y1 - 1994

N2 - Secondary hyperparathyroidism in chronic renal failure may contribute to abnormalities of lipid metabolism and glucose tolerance. Amelioration of secondary hyperparathyroidism has been reported to mitigate the hyperlipidaemia and improve glucose tolerance experimentally. The effect of the partial suppression of hyperparathyroidism by intravenous calcitriol on lipid levels and glucose tolerance was studied in 15 haemodialysis patients with secondary hyperparathyroidism. All received intravenous calcitriol 1 μg at the end of haemodialysis thrice weekly for eight weeks. Oral glucose tolerance test and plasma lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apoprotein A-I and apoprotein B were determined simultaneously before and after eight weeks of therapy. Before calcitriol treatment, uraemic patients with secondary hyperparathyroidism displayed a significant higher triglyceride and a significant lower HDL-C and apoprotein A-I as well as marked glucose intolerance with an increment of the area below the glucose curve when compared with healthy control subjects. After eight weeks of calcitriol treatment, there was a significant decrement in serum intact parathyroid hormone (476.45 ± 48.33 versus 191.37 ± 30.17 ng/l, P <0.001) and plasma triglyceride (2.24 ± 0.34 versus 1.80 ± 0.29 mmol/l, P <0.05) as well as a significant increment of plasma apoprotein A-I (38.13 ± 2.14 versus 44.19 ± 2.18 μmol/l, P <0.05), whereas there was no significant change in serum total cholesterol, LDL-C, HDL-C, and apoprotein B. These patients also became more glucose tolerant with a significant decrease of the area below the glucose curve and a significant rise in the area under the insulin curve after glucose load. Furthermore, the insulinogenic index increased significantly. It was concluded that in addition to 1,25-dihydroxyvitamin D3 deficiency, secondary hyperparathyroidism may participate in the abnormal lipid metabolism, glucose tolerance and insulin secretion seen in dialysis patients and these abnormalities could be, at least in part, improved by intravenous calcitriol treatment.

AB - Secondary hyperparathyroidism in chronic renal failure may contribute to abnormalities of lipid metabolism and glucose tolerance. Amelioration of secondary hyperparathyroidism has been reported to mitigate the hyperlipidaemia and improve glucose tolerance experimentally. The effect of the partial suppression of hyperparathyroidism by intravenous calcitriol on lipid levels and glucose tolerance was studied in 15 haemodialysis patients with secondary hyperparathyroidism. All received intravenous calcitriol 1 μg at the end of haemodialysis thrice weekly for eight weeks. Oral glucose tolerance test and plasma lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apoprotein A-I and apoprotein B were determined simultaneously before and after eight weeks of therapy. Before calcitriol treatment, uraemic patients with secondary hyperparathyroidism displayed a significant higher triglyceride and a significant lower HDL-C and apoprotein A-I as well as marked glucose intolerance with an increment of the area below the glucose curve when compared with healthy control subjects. After eight weeks of calcitriol treatment, there was a significant decrement in serum intact parathyroid hormone (476.45 ± 48.33 versus 191.37 ± 30.17 ng/l, P <0.001) and plasma triglyceride (2.24 ± 0.34 versus 1.80 ± 0.29 mmol/l, P <0.05) as well as a significant increment of plasma apoprotein A-I (38.13 ± 2.14 versus 44.19 ± 2.18 μmol/l, P <0.05), whereas there was no significant change in serum total cholesterol, LDL-C, HDL-C, and apoprotein B. These patients also became more glucose tolerant with a significant decrease of the area below the glucose curve and a significant rise in the area under the insulin curve after glucose load. Furthermore, the insulinogenic index increased significantly. It was concluded that in addition to 1,25-dihydroxyvitamin D3 deficiency, secondary hyperparathyroidism may participate in the abnormal lipid metabolism, glucose tolerance and insulin secretion seen in dialysis patients and these abnormalities could be, at least in part, improved by intravenous calcitriol treatment.

KW - 1,25-(OH)D, 1,25-dihydroxyvitamin D

KW - alb, albumin

KW - apo, apoprotein

KW - HDL-C, high density lipoprotein cholesterol

KW - HTGL, hepatic triglyceride lipase

KW - I-PTH, intact parathyroid hormone

KW - ICa, ionized calcium

KW - InP, inorganic phosphorus

KW - LDL-C, low density lipoprotein cholesterol

KW - LPL, lipoprotein lipase

KW - OGTT, oral glucose tolerance test

KW - PTH, parathyroid hormone

KW - TC, total cholesterol

KW - TCa, total calcium

KW - TG, triglyceride

UR - http://www.scopus.com/inward/record.url?scp=0028043745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028043745&partnerID=8YFLogxK

M3 - Article

C2 - 7874841

AN - SCOPUS:0028043745

VL - 87

SP - 533

EP - 538

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 5

ER -